The CMA responds to Health Canada’s proposed regulatory amendments governing medicinal cannabis, raising concerns about the scarcity of evidence for using cannabis as medical therapy as well as other objections to the existing regulatory framework
The CMA responds to Health Canada’s proposed regulatory amendments governing medicinal cannabis, raising concerns about the scarcity of evidence for using cannabis as medical therapy as well as other objections to the existing regulatory framework